Abstract
To determine the status of chromosome 10q23 in primary breast carcinomas, in situ and invasive carcinomas were analysed for allelic loss using microsatellite markers spanning the 10q23 region. No LOH was seen in pure intraductal carcinomas (0/20 cases). On the other hand, LOH was observed in 40% (17/42) of invasive carcinomas (P=0.0005). Interestingly, in situ lesions found in invasive tumors displayed LOH. Allelic loss was also significantly associated with loss of the estrogen receptor (P=0.011). Thus, loss of the 10q23 is strongly associated with tumor progression.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bose, S., Wang, S., Terry, M. et al. Allelic loss of chromosome 10q23 is associated with tumor progression in breast carcinomas. Oncogene 17, 123–127 (1998). https://doi.org/10.1038/sj.onc.1201940
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1201940
- Springer Nature Limited
Keywords
This article is cited by
-
A study on promoter methylation of PTEN in sporadic breast cancer patients from North India
Breast Cancer (2016)
-
Expression of Somatostatin Receptor Type 2A and PTEN in Neuroendocrine Neoplasms Is Associated with Tumor Grade but Not with Site of Origin
Endocrine Pathology (2016)
-
A novel deleterious PTEN mutation in a patient with early-onset bilateral breast cancer
BMC Cancer (2014)
-
The PI3K/AKT/MTOR Signaling Pathway: The Role of PI3K and AKT Inhibitors in Breast Cancer
Current Breast Cancer Reports (2014)
-
The Role of the Insulin-like Growth Factor-1 Receptor (IGF-1R), Phosphatase and Tensin Homolog (PTEN), c-Met, and the PI3-Kinase Pathway in Colorectal Cancer
Current Colorectal Cancer Reports (2012)